Jeffrey David Hulmes

Title: The Innovations of Jeffrey David Hulmes

Introduction

Jeffrey David Hulmes is a notable inventor based in Ringwood, NJ (US). He has made significant contributions to the field of biotechnology, particularly in the development of cytokine proteins. With a total of six patents to his name, his work has had a profound impact on medical research and treatment.

Latest Patents

One of Hulmes' latest patents is focused on the purification and characterization of a novel cytokine protein known as IL-12, or Cytotoxic Lymphocyte Maturation Factor (CLMF). This protein is produced and synthesized by human NC-37 B lymphoblastoid cells. The invention highlights how CLMF synergistically induces the cytolytic activity of Lymphokine Activated Killer (LAK) cells when combined with low concentrations of IL-2. Additionally, CLMF is capable of stimulating T-cell growth. The patent also claims the cloned gene for CLMF, its recombination in a suitable vector, the transformed cells containing said vector, the recombinant protein produced by these transformed cells, and antibodies to CLMF.

Career Highlights

Throughout his career, Jeffrey David Hulmes has worked with prominent companies such as Hoffmann-La Roche Inc. and American Cyanamid Company. His experience in these organizations has contributed to his expertise in the field of biotechnology and patent development.

Collaborations

Hulmes has collaborated with notable individuals in his field, including Maurice Kent Gately and Ulrich Andreas Gubler. These collaborations have likely enhanced his research and innovation efforts.

Conclusion

Jeffrey David Hulmes is a distinguished inventor whose work in cytokine proteins has advanced medical research. His patents reflect his commitment to innovation and the betterment of healthcare solutions.